SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRANCHINI, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.181
AS - Asia 4.434
EU - Europa 3.328
SA - Sud America 676
AF - Africa 90
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
Totale 16.728
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.977
SG - Singapore 1.869
IT - Italia 1.351
CN - Cina 1.237
BR - Brasile 572
DE - Germania 490
HK - Hong Kong 422
PL - Polonia 301
VN - Vietnam 273
GB - Regno Unito 243
UA - Ucraina 225
TR - Turchia 184
FI - Finlandia 151
ID - Indonesia 126
RU - Federazione Russa 122
CA - Canada 110
SE - Svezia 101
IN - India 90
MX - Messico 84
FR - Francia 79
NL - Olanda 62
JP - Giappone 43
ZA - Sudafrica 41
AR - Argentina 40
BD - Bangladesh 32
BE - Belgio 31
CZ - Repubblica Ceca 29
ES - Italia 29
EC - Ecuador 23
IQ - Iraq 22
LT - Lituania 18
IR - Iran 17
RO - Romania 16
AT - Austria 15
TW - Taiwan 15
DK - Danimarca 14
PK - Pakistan 14
NO - Norvegia 12
MA - Marocco 11
CL - Cile 10
EU - Europa 10
MY - Malesia 10
SA - Arabia Saudita 10
IE - Irlanda 9
JO - Giordania 9
KR - Corea 9
CO - Colombia 8
KE - Kenya 8
VE - Venezuela 8
AU - Australia 7
EG - Egitto 7
IL - Israele 7
PT - Portogallo 7
AE - Emirati Arabi Uniti 6
DZ - Algeria 6
UY - Uruguay 6
UZ - Uzbekistan 6
CH - Svizzera 5
NP - Nepal 5
AZ - Azerbaigian 4
GE - Georgia 4
NG - Nigeria 4
PY - Paraguay 4
AL - Albania 3
ET - Etiopia 3
GR - Grecia 3
PE - Perù 3
TN - Tunisia 3
AF - Afghanistan, Repubblica islamica di 2
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
PA - Panama 2
PH - Filippine 2
SN - Senegal 2
TH - Thailandia 2
AO - Angola 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
DM - Dominica 1
EE - Estonia 1
GA - Gabon 1
GH - Ghana 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
Totale 16.722
Salva come PNG Salva come JPEG
Città #
Singapore 1.047
Dallas 1.008
Ashburn 762
Chandler 570
Fairfield 504
Santa Clara 476
Woodbridge 441
Beijing 417
Hong Kong 401
Ferrara 350
Warsaw 296
Houston 284
Ann Arbor 277
New York 224
Wilmington 221
Seattle 219
Jacksonville 216
Los Angeles 184
Cambridge 173
Munich 161
Izmir 119
Princeton 118
Milan 115
Jakarta 104
Nanjing 101
Shanghai 93
Dearborn 88
Ho Chi Minh City 82
São Paulo 70
Boardman 65
Helsinki 63
Bremen 62
The Dalles 61
Hanoi 59
Mexico City 50
London 48
Rome 48
San Diego 46
Turku 43
Redwood City 41
Toronto 40
Brooklyn 38
Denver 37
Bologna 36
Nanchang 36
Falls Church 35
Montreal 34
Atlanta 33
Shenyang 33
Tokyo 33
Florence 31
Frankfurt am Main 28
Orem 28
Poplar 28
Falkenstein 26
Moscow 26
Tianjin 26
Brussels 25
Chicago 25
Guangzhou 25
Hefei 25
Chennai 23
Dong Ket 23
Johannesburg 23
Phoenix 23
Hebei 21
Jiaxing 21
Auburn Hills 20
Nuremberg 20
San Mateo 20
Buffalo 19
San Francisco 19
Brno 17
Changsha 17
Jinan 17
Rio de Janeiro 17
Kunming 16
Manchester 16
Boston 15
Columbus 15
Hangzhou 15
Norwalk 15
Stockholm 15
Amsterdam 14
Zhengzhou 14
Monza 13
Ankara 12
Haiphong 12
Mumbai 12
Washington 12
Belo Horizonte 11
Brasília 11
Charlotte 11
Curitiba 11
Mountain View 11
Ningbo 11
Naples 10
Praia A Mare 10
Querétaro 10
Taipei 10
Totale 10.957
Salva come PNG Salva come JPEG
Nome #
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 946
La sanificazione delle degenze ospedaliere: nuove strategie per la riduzione delle infezioni correlate all’assistenza sanitaria 392
La sanificazione delle degenze ospedaliere: nuove strategie a supporto della riduzione delle infezioni correlate all’assistenza sanitaria 361
Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation 307
Il sistema di sanificazione PCHS Probiotic Cleaning Hygien System: risultati delle indagini sperimentali in vitro e in campo 275
The carboxyl-terminal region of coagulation factors: role in biosynthesis and function of FVII and FX 268
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 262
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 249
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 246
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 235
PCHS (Probiotic Hygiene Cleaning System) Protocol: reduction of hospital environmental impact with a new and innovative technology for cleaning in Ferrara University Hospital 223
Hard surface biocontrol in hospitals using microbial-based cleaning products 219
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 204
Reduction of the microbial load on hospital surfaces through probiotic-based cleaning procedures: a new strategy to control nosocomial infections 200
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 200
Chronic sleep deprivation markedly reduces coagulation factor VII expression 191
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 183
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 183
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 182
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 181
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 178
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 178
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 174
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 169
I probiotici: aspetti generali e valutazioni sulla sicurezza d’impiego 169
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 169
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 164
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 160
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 157
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 153
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 153
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 152
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 150
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 149
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 148
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 147
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 147
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 141
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 140
F9 genotype and PK hemophilia B international study (GEPKHIS) 139
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 138
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 137
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 137
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 136
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 134
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 130
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 130
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 129
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 129
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 129
Characterization of PAR-mediated signaling induced by activated coagulation factor X mutants 127
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 127
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 127
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 126
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 124
An engineered factor X variant as a novel by-passing agent for hemophilia 120
A recoded view on the F9 p.Cys178Ter pathogenic mechanism 120
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 119
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 119
Improved intracellular processing of protein variants as a personalized therapeutic approach for Haemophilia 118
Hemostasis gene expression of the internal jugular and saphenous veins 118
Exploring spontaneous readthrough over recurrent F8 nonsense mutations: potential correlation with inhibitor risk? 118
Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches 117
Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies 116
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 116
Academic Editor per la rivista PLoS One 115
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 114
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 113
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 112
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 106
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 105
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity 104
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 102
Comparative Analysis Of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B- domain Favours Readthrough- mediated Protein Output 101
MOLECULAR MECHANISMS AND THERAPEUTIC APROACHES FOR RESTORATION OF mRNA TRANSCRIPTION, MATURATION AND TRANSLATION IN INHERITED COAGULATION FACTOR DEFICIENCIES 100
Effects of Partial Chronic Sleep Deprivation on the Mouse Blood Coagulation Cascade. 100
Engineered transcription factors (TALE-TF) as potential therapeutic strategy for coagulation factor deficiencies caused by promoter mutations 99
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations 99
The FVII R402X nonsense mutation, associated with an asymptomatic phenotype, is responsible for small amounts of circulating protein with improved coagulant activity 99
An integrated multi-tool analysis contributes elements to interpreting unclassified factor IX missense variants associated with haemophilia B 96
Next generation factor VIIa with enhanced half-life 95
null 94
null 93
A factor X variant with engineered activation peptide as innovative by-passing agent for haemophilia 93
Translation termination codons in protein synthesis and disease 92
A new type 1 von Willebrand Disease (VWD) characterized by increased clearance of von Willebrand Factor (VWF) due to the heterozygous p.P1127S mutation: clinical phenotype and pathogenic mechanisms 92
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 91
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 91
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 90
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 88
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 87
Naturally occurring truncated proteins: decreased protein secretion and increased activity result in asymptomatic coagulation factor deficiency 86
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 84
null 84
The carboxyl-terminal region of coagulation serine proteases: A matter of cut and change 84
Genotype and PK Hemophilia B International Study (GePKHIS) - A progress Report 80
Associate Editor per la rivista Frontiers in Pediatrics - sezione Genetic Disorders 79
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 75
“Compensatory” aberrant splicing supports residual expression levels in severe coagulation factor VII deficiency 74
Engineered suppressor tRNAs as a novel correction approach for recurrent hemophilia A-causing nonsense mutations 73
Totale 15.075
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.049
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 553
Totale 82.602
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.075 0 0 0 0 0 100 255 176 82 198 179 85
2021/20221.181 170 139 37 36 82 72 49 48 35 84 74 355
2022/20231.242 132 144 50 174 179 158 77 79 135 11 58 45
2023/2024856 63 67 44 32 54 156 41 62 29 33 44 231
2024/20253.349 102 78 302 108 394 371 78 90 523 383 507 413
2025/20265.631 944 550 1.259 1.308 1.385 185 0 0 0 0 0 0
Totale 17.119